My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 269

    1.

    Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.

    Ceriello A, Piconi L, Quagliaro L, Wang Y, Schnabel CA, Ruggles JA, Gloster MA, Maggs DG, Weyer C.

    Diabetes Care. 2005 Mar;28(3):632-7.PMID: 15735200 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes.

    Ceriello A, Lush CW, Darsow T, Piconi L, Corgnali M, Nanayakkara N, Frias JP, Maggs D.

    Diabetes Metab Res Rev. 2008 Feb;24(2):103-8.PMID: 17694505 [PubMed - indexed for MEDLINE]Related articles

    3.

    Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.

    Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C.

    Diabetes Metab Res Rev. 2004 Jan-Feb;20(1):55-60.PMID: 14737746 [PubMed - indexed for MEDLINE]Related articles

    4.

    Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

    Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.

    Diabetes Care. 2003 Nov;26(11):3074-9.PMID: 14578242 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.

    Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR.

    Diabetes Care. 2003 Jan;26(1):1-8.PMID: 12502651 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.

    Nyholm B, Orskov L, Hove KY, Gravholt CH, Møller N, Alberti KG, Moyses C, Kolterman O, Schmitz O.

    Metabolism. 1999 Jul;48(7):935-41.PMID: 10421239 [PubMed - indexed for MEDLINE]Related articles

    7.

    A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.

    Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O.

    Diabetes Care. 2006 Oct;29(10):2189-95.PMID: 17003291 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.

    Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG.

    Metabolism. 2002 May;51(5):636-41.PMID: 11979398 [PubMed - indexed for MEDLINE]Related articles

    9.

    Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.

    Singh-Franco D, Robles G, Gazze D.

    Clin Ther. 2007 Apr;29(4):535-62. Review.PMID: 17617279 [PubMed - indexed for MEDLINE]Related articles

    10.

    Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.

    Kovatchev BP, Crean J, McCall A.

    Diabetes Technol Ther. 2008 Oct;10(5):391-6.PMID: 18715216 [PubMed - indexed for MEDLINE]Related articles

    11.

    The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.

    Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG.

    Horm Metab Res. 2002 Sep;34(9):504-8.PMID: 12384827 [PubMed - indexed for MEDLINE]Related articles

    12.

    Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.

    Chase HP, Lutz K, Pencek R, Zhang B, Porter L.

    J Pediatr. 2009 Sep;155(3):369-73. Epub 2009 May 21.PMID: 19464026 [PubMed - indexed for MEDLINE]Related articles

    13.

    Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes.

    Kipnes M, Dandona P, Tripathy D, Still JG, Kosutic G.

    Diabetes Care. 2003 Feb;26(2):421-6.PMID: 12547873 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.

    Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A.

    Diabetologia. 1996 Apr;39(4):492-9.PMID: 8778001 [PubMed - indexed for MEDLINE]Related articles

    15.

    Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes.

    Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG.

    Diabet Med. 1997 Jul;14(7):547-55.PMID: 9223392 [PubMed - indexed for MEDLINE]Related articles

    16.

    Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

    Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG.

    Diabet Med. 2004 Nov;21(11):1204-12.PMID: 15498087 [PubMed - indexed for MEDLINE]Related articles

    17.

    The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.

    Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW.

    Diabetes. 2005 Apr;54(4):1100-7.PMID: 15793249 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.

    Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O.

    Diabetes Care. 2007 Nov;30(11):2794-9. Epub 2007 Aug 13.PMID: 17698615 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients.

    Assaloni R, Da Ros R, Quagliaro L, Piconi L, Maier A, Zuodar G, Motz E, Ceriello A.

    Diabetologia. 2005 Sep;48(9):1919-24. Epub 2005 Jul 9.PMID: 16007412 [PubMed - indexed for MEDLINE]Related articles

    20.

    Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial.

    Thompson RG, Peterson J, Gottlieb A, Mullane J.

    Diabetes. 1997 Apr;46(4):632-6.PMID: 9075803 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity